Ribociclib
novartis
['breast', 'novartis']
today at #asco23, learn more from dr el saghir about results from a subgroup analysis from the phase ii right choice study in patients with aggressive hr+/her2-advanced #breastcancer including life-threatening visceral crises. 
Committed to providing medical & scientific disease education information to healthcare professionals. See our community guidelines: https://t.co/pj8hG1sQAu